ECTRIMS 2022

Evolution of the RebiSmart® Autoinjector Device in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for Relapsing Multiple Sclerosis

Arnaud | Poster #EP1079

Immune Response Following mRNA COVID-19 Vaccination in Patients with Multiple Sclerosis Treated with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib

Bar-Or | Poster #1188

B Cells Infiltrating the MS Brain: From Local Maturation to Targeting by Evobrutinib

Bogers | Poster #147

Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: The CLARENCE Study

Brownlee | Poster #762

Exploring the Relationship Between Serum GDF-15 and Disease Stability in Patients with a First Clinical Demyelinating Event Treated with Subcutaneous Interferon β-1a or Placebo in the REFLEX Study

Coray | Poster #EP1027

Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study

De Stefano | Poster #717

Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, Acts on Microglia: Implications in the Treatment of Progressive Mechanisms In Multiple Sclerosis

Geladaris | Poster #693

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Liver Safety

Giovannoni | Poster #341

Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, Decreases Serum Neurofilament Light Chain Levels Over 2.5 Years of Treatment, in Patients with Relapsing Multiple Sclerosis

Kuhle | Poster #EP1021

High Adherence and Minimal Delays of Year 2 Treatment in People with Multiple Sclerosis Treated with Cladribine Tablets: Results from Multi-Country Patient Support Programmes

Oh |Poster #727

Maven4: Phase IV Non-Interventional, Prospective, Spanish Multicenter Study to Evaluate Cladribine Tablets Long-Term Effectiveness on Real-World Clinical Practice

Saiz | Poster #774

Evobrutinib Exerts a Therapeutic Action on EAE by Increasing the Peripheral and Central Classical Dendritic Cell Number and Maturation

Serrano-Regal | Poster #307

Improvements in Quality of Life Over 2 Years in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS

Solari | Poster #108

MRI and Clinical Outcomes of Evobrutinib, A Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial

Vermersch |Poster #731

Treatment Emergent Adverse Events Experienced Early and Transiently in the Treatment Course with Cladribine Tablets: Data from the CLEVER Real-World Study

Ziemssen | Poster #772